Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Amperozide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 7/20 | 0.65 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.65 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.95 |
| ▸ | MTOR | P42345 | 2/20 | 0.95 |
| ▸ | RAB9A | P51151 | 2/20 | 0.95 |
| ▸ | FAAH | O00519 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.95 |
| ▸ | MEN1 | O00255 | 3/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.93 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | HRH1 | P35367 | 8/20 | 0.65 |
| ▸ | HTR2A | P28223 | 7/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amperozide SCHEMBL340961 | 0.98 | CYP3A4 (1.00) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| Amperozide SCHEMBL1321270 | 0.97 | MEN1 (1.00) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| SCHEMBL10556167 | 0.88 | CYP3A4 (0.83) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| Hydrochloric Acid SCHEMBL10510286 | 0.87 | MEN1 (0.83) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| Hydrochloric Acid SCHEMBL10510024 | 0.86 | KMT2A (0.81) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| Oxalic Acid SCHEMBL10506155 | 0.85 | MAPK1 (0.77) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| Hydrochloric Acid SCHEMBL10507007 | 0.84 | MEN1 (0.78) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| SCHEMBL10557106 | 0.84 | CYP3A4 (0.74) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| SCHEMBL10506450 | 0.84 | MAPK1 (0.74) | CYP3A4CYP2D6MAPK1MTORRAB9A | |
| SCHEMBL10509222 | 0.82 | MAPK1 (0.72) | CYP3A4CYP2D6MAPK1MTORRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220323456-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2022-10-13 | — | — | US | disclosed |
| US-11337984-B2 | Methods for treating, diagnosing and prognosing a haematological malignancy | INSTITUT DE RECERCA CONTRA LA LEUCÉMIA JOSEP CARRERAS (ES) | 2022-05-24 | — | — | US | disclosed |
| US-20210228593-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2021-07-29 | — | — | US | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| EP-3713568-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-09-30 | — | — | EP | disclosed |
| EP-3160472-B1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INST DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS (ES) | 2020-03-11 | — | — | EP | disclosed |
| US-20190343843-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2019-11-14 | — | — | US | disclosed |
| CN-106471373-B | For treating, diagnosing and the method for prognosis Malignancy | 约瑟卡雷拉斯白血球过多症研究所 | 2019-08-23 | — | — | CN | disclosed |
| US-10195207-B2 | Methods for treating, diagnosing and prognosing a haematological malignancy | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2019-02-05 | — | — | US | disclosed |
| US-20170143735-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS (ES) | 2017-05-25 | — | — | US | disclosed |
| EP-3160472-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | Institut De Recerca Contra La Leucemia Josep Carreras (ES) | 2017-05-03 | — | — | EP | disclosed |
| CN-106471373-A | For treat, diagnose and prognosis Malignancy method | 约瑟卡雷拉斯白血球过多症研究所 | 2017-03-01 | — | — | CN | disclosed |
| EP-2959904-A1 | Methods for treating, diagnosing and prognosing a haematological malignancy | Institut De Recerca Contra La Leucemia Josep Carreras (ES) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015197839-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | SLC6A3 44/4885TACR1 59/4885CHRM3 501/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | SLC6A3 41/4885TACR1 63/4885CHRM3 481/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | SLC6A3 44/4885TACR1 59/4885CHRM3 501/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | SLC6A3 44/4885TACR1 59/4885CHRM3 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.